Project Grant R21CA313483
Award Date 6/1/26
Completion Date 5/31/28
Dollars Obligated $480K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $2.49M Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research, effective August 1, 2025, through July 31, 2030. This research initiative comprises three integrated projects investigating lipid metabolism as a determinant of ferroptosis sensitivity in cancer cells. Project 1, led by Dr. Xuejun Jiang at Memorial Sloan Kettering Cancer Institute, examines how...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary Sinopia Biosciences Inc. received a $285,599 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on September 22, 2025, with a completion date of August 31, 2027. The award supports the development of a metabolomics-enabled artificial intelligence/machine learning (AI/ML) platform designed to discover new treatments that enhance drug sensitivity in cancer. Working in collaboration with Omix...
- Federal Grant Award Summary The J. David Gladstone Institutes received a $1.37M Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) beginning August 1, 2025 and concluding May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The primary deliverable is an innovative preclinical research platform that...
- Federal Project Grant Award Summary The Scintillon Institute received a $501,160 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded May 1, 2026, with a completion date of April 30, 2028. Under this award, the institute will develop and validate novel genetically encoded tools designed to directly manipulate nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) redox cofactor ratios in specific tissues and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $182,755.00 to Cold Spring Harbor Laboratory through the Cancer Biology Research program (CFDA 93.396) to support research on genetic technology development for elucidating lineage plasticity mechanisms in cancer. The project, which commenced on August 21, 2025, and is scheduled for completion on July 31, 2030, will deliver advanced genetic screening technologies and methodologies designed to probe lineage identity...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $402,135 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, with completion targeted for April 30, 2029. The award funds development and optimization of SCHICAR (Single-Cell High-resolution Integrated Chromatin And aRchitecture), an innovative tri-modal single-cell platform that simultaneously captures...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant totaling $614,260 under the Cancer Biology Research program (CFDA 93.396) for the period May 11, 2026 through April 30, 2031. This five-year award supports fundamental research investigating the mechanisms by which hypoxia regulates ferroptosis, an iron-dependent form of programmed cell death implicated in cancer suppression. The research aims to elucidate...